This is a repository copy of *A systematic review of the variability of ventilation defect percent generated from hyperpolarized noble gas pulmonary magnetic resonance imaging*.

White Rose Research Online URL for this paper:
https://eprints.whiterose.ac.uk/223959/

Version: Published Version

Article:
Diamond, V.M. orcid.org/0000-0001-8314-5130, Bell, L.C., Bone, J.N. et al. (13 more authors) (2025) A systematic review of the variability of ventilation defect percent generated from hyperpolarized noble gas pulmonary magnetic resonance imaging. Journal of Magnetic Resonance Imaging. ISSN 1053-1807

https://doi.org/10.1002/jmri.29746

Reuse
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here: https://creativecommons.org/licenses/

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/

Check for updates

Journal of Magnetic Resonance Imaging

REVIEW OPEN ACCESS

A Systematic Review of the Variability of Ventilation Defect Percent Generated From Hyperpolarized Noble Gas Pulmonary Magnetic Resonance Imaging

Vanessa M. Diamond[1] | Laura C. Bell[2] | Jeffrey N. Bone[1] | Bastiaan Driehuys[3] | Martha Menchaca[4] | Giles Santyr[5,6] | Sarah Svenningsen[7,8] | Robert P. Thomen[9] | Helen Marshall[10,11] | Laurie J. Smith[10,11] | Guilhem J. Collier[10,11] | Jim M. Wild[10,11] | Jason C. Woods[12,13] | Sean B. Fain[14] | Rachel L. Eddy[1,15,16,17] | Jonathan H. Rayment[1,15,17]

[1]BC Children's Hospital Research Institute, University of British Columbia, Vancouver, British Columbia, Canada | [2]Clinical Imaging Group, Genentech, San Francisco, California, USA | [3]Department of Radiology, Duke University, Durham, North Carolina, USA | [4]Department of Radiology, University of Illinois at Chicago, Chicago, Illinois, USA | [5]Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada | [6]Translational Medicine Program, The Hospital for Sick Children, Toronto, Ontario, Canada | [7]Firestone Institute for Respiratory Health, the Research Institute of St. Joe's Hamilton, McMaster University, Hamilton, Ontario, Canada | [8]Department of Medicine, McMaster University, Hamilton, Ontario, Canada | [9]Department of Radiology, School of Medicine, University of Missouri, Columbia, Missouri, USA | [10]POLARIS, Section of Medical Imaging and Technologies, Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK | [11]Insigneo Institute, University of Sheffield, Sheffield, UK | [12]Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA | [13]Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA | [14]Department of Radiology, University of Iowa, Iowa City, Iowa, USA | [15]UBC Centre for Heart Lung Innovation, University of British Columbia, Vancouver, British Columbia, Canada | [16]Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada | [17]Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada

Correspondence: Jonathan H. Rayment (jonathan.rayment@bcchr.ca)

Received: 22 November 2024 | **Revised:** 4 February 2025 | **Accepted:** 5 February 2025

Keywords: hyperpolarized 129Xe | hyperpolarized 3He | hyperpolarized noble gas | non-proton MRI | pulmonary MRI | ventilation defect percent

ABSTRACT

Hyperpolarized (HP) gas pulmonary MR ventilation images are typically quantified using ventilation defect percent (VDP); however, the test-retest variability of VDP has not been systematically established in multi-center trials. Herein, we perform a systematic review of the test-retest literature on the variability of VDP, and similar metrics, generated from HP MRI. This review utilizes the Medline, EMBASE, and EBM Reviews databases and includes studies that assessed the variability of HP MRI VDP. The protocol was registered to PROSPERO: CRD42022328535. Imaging techniques and statistical analysis characteristics were extracted and used to group studies to evaluate the overall ability to pool data across grouped studies. The ability to pool data to provide systematic evidence was assessed using a modified COSMIN tool. A total of 22 studies with 37 distinct aims for repeated HP MRI acquisition or quantification were included. Studies were grouped into six categories based on HP gas and analysis type: repeated imaging (^{129}Xe $n = 13$, ^{3}He $n = 12$), interobserver repeated analysis (^{129}Xe $n = 4$, ^{3}He $n = 4$) or intraobserver repeated analysis (^{129}Xe $n = 1$, ^{3}He $n = 2$). Studies assessed variability using a variety of statistical tests including absolute difference, percent coefficient of variation, Bland-Altman limits of agreement, coefficient of reproducibility, or the intra-class correlation. Individual studies generally reported low variability of VDP (ICC range: 0.5–1.0; Bland-Altman bias range: −6.9–20%), but there was an overall inability to pool data and provide a meta-analysis due to methodological inconsistencies and small sample size. Overall, we found that VDP has low variability in most studies. However, inconsistent image acquisition and quantification methodologies between studies limits direct comparability and precludes grouping of study

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2025 The Author(s). *Journal of Magnetic Resonance Imaging* published by Wiley Periodicals LLC on behalf of International Society for Magnetic Resonance in Medicine.

data for meta-analyses. Despite early efforts to standardize HP MRI acquisition, further work is necessary to standardize VDP quantification to allow broader validation and clinical implementation.
Evidence Level: 2
Technical Efficacy: Stage 3

1 | Introduction

Sufficient monitoring of lung health is necessary for disease management by respiratory care teams worldwide. Spirometry is routinely used to assess and monitor lung function, with forced expiratory volume in one second (FEV_1) or forced vital capacity (FVC) being the primary clinical outcome measures [1, 2]. However, spirometry provides only a global measurement of total lung function that is known to be insensitive to disease heterogeneity and early small airways disease [2]. Chest x-ray is commonly used to visualize and measure lung structure but is two-dimensional and does not routinely provide functional information. Chest CT imaging provides three-dimensional high spatial resolution and can indirectly provide functional information; however, radiation exposure limits frequent monitoring [3]. Consequently, there is a great need for tools that are safe and sensitive to early and heterogeneous alterations in lung function.

Hyperpolarized (HP) gas magnetic resonance imaging (MRI) of the lungs uses inhaled 3-helium (^{3}He) or 129-xenon (^{129}Xe) gas to measure lung function [4]. Results from these gases have been shown to not be directly comparable due to the nature of the different nuclei [5–7]; however, both have been established as safe and feasible in adults and pediatrics [8–11]. The most common HP MRI technique utilizes the spin-density of inhaled hyperpolarized nuclei to visualize and quantify the intrapulmonary distribution of the tracer gas (or "static ventilation") and is now approved for clinical use in the United States and the United Kingdom [12, 13]. Ventilation defect percent (VDP) is a widely reported quantitative outcome measure derived from static ventilation MRI, which quantifies the fraction of the lungs that does not receive gas after a single inhalation during a breath hold maneuver. In many single-center studies, VDP has been shown to be correlated with FEV_1 across multiple pulmonary disorders [14–16]. Additionally, VDP has been shown to be highly sensitive to abnormal lung function and related to important patient outcomes across single-center studies. For example, in chronic obstructive pulmonary disease (COPD), VDP demonstrated a significant increase over 2 years while FEV_1 remained constant [17]. Another study showed that baseline VDP predicted future COPD exacerbations [18]. Compared to spirometry, VDP has also been shown to be more sensitive to abnormal lung function in people with cystic fibrosis (CF) and in children following hematopoietic stem cell transplantation [19–22]. Additionally, in asthma, baseline VDP has been shown to be related to prior hospitalizations [23] and predictive of future exacerbations [24]. VDP has also been demonstrated to be highly sensitive to treatment response in COPD, CF, and asthma [7, 25, 26]. Taken together, these studies provide evidence for VDP as a powerful and clinically relevant pulmonary outcome measure. Some studies have endeavored to define thresholds for clinically important change in VDP to support clinical decisions [27–30]. However, due to the nature of the relatively small and heterogeneous single-center studies to date, unanswered questions remain surrounding the limits of normal and clinically important changes for VDP.

Of primary importance, the test–retest variability of VDP must be clearly established to determine limits of normal and clinically important changes and assess its utility in comparison to conventional measures of lung function. In this context, variability reflects how much an outcome can be expected to change over repeat assessments in a stable individual [31]; variability can result from multiple sources, including technological acquisition, inter- and intraobserver measurement variation, defect quantification technique, and bio-physiologic variations, such as lung inflation state, that are unrelated to disease [32], as well as disease-specific differences. An understanding of measurement variability allows clinicians and end-users to better interpret clinical measurements; for example, the biological variability and measurement error of FEV_1 is well established as 100 mL absolute change or 10% relative change, which underpins much of the interpretation of this test [33]. To date, the variability of VDP has not been well established beyond single center studies. Therefore, the purpose of this systematic review was to assess the current literature on the test–retest variability of VDP (and similar metrics) as an outcome measure of HP MRI across multiple sites and studies.

2 | Materials and Methods

2.1 | Search Strategy

The Medline, EMBASE, and EBM Reviews databases were searched by one author (V.M.D.) using the Ovid search platform. Key search terms included: "respiratory tract disease," "magnetic resonance imaging," "hyperpolarized noble gas," "ventilation defect," "reproducibility," and "variability." The full search queries are included in Supplement. Studies were included from database inception until October 20th, 2024, for each database. This systematic review and full electronic search strategy were registered with the international prospective register of systematic reviews (PROSPERO CRD42022328535) before beginning data extraction [34]. Gray literature (work published outside of traditional channels [35]) was not included in this review; only peer-reviewed literature published in English was included. Two authors (V.M.D. and R.L.E.) independently screened all titles and abstracts, after which full-text review for eligibility was performed independently on relevant titles and abstracts. A third author (J.H.R.) resolved conflicts in eligibility decisions.

2.2 | Eligibility

For this review, we included publications that evaluated the variability of VDP in healthy people and those with clinically

15222586, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/jmri.29746 by Test, Wiley Online Library on [03/03/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

diagnosed respiratory disease through either repeated imaging or repeated measurement quantification. Studies will be grouped for comparison according to the type of variability assessed (i.e., repeated scans, and/or intra/interobserver repeated quantification). To be eligible, studies must have reported VDP as an outcome measure generated from HP MRI or a similar metric with previous terminology such as ventilated volume (VV) or reader defect volume. Studies must have also reported one or more of the following measures of statistical metrics for the reported outcome: absolute difference, percent coefficient of variation, Bland–Altman limits of agreement, coefficient of reproducibility, or the intra-class correlation coefficient. Study design was not restricted. Duplicate publications and studies reporting duplicate data were excluded using the Covidence software [36]. Studies using animal models and studies assessing technology feasibility were excluded.

2.3 | Quality Assessment

The study design and results were assessed using the COSMIN extended criteria for good reliability and measurement error by two authors (V.M.D. and R.L.E.) [37, 38]. Study outcomes were rated based on whether they assessed reliability or measurement error as defined by the Good Measurement Properties (GMP) guidelines [37, 38]. Reliability was defined as the proportion of variance in the measurements due to true differences between repeated scans and was rated sufficient if an intra-class correlation (ICC) of greater than or equal to 0.7 was reported. If no ICC was reported, reliability was rated indeterminate. Measurement error was defined as systematic and random error in repeated VDP analysis measurements, that is not attributed to true changes in VDP (i.e., inter- or intra-observer VDP measurement variability). COSMIN criteria define sufficient evidence of adequate measurement error if the smallest detectable change of limits of agreement is less than the minimal important change; as there is no consensus on the minimal important change (MIC) of VDP, all work assessing measurement error was thus rated indeterminate by these criteria.

The modified Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was used to assess the certainty of combined evidence across the included studies (Table S1) [38–40]. To accommodate study designs and the assessment of different aspects of variability, studies were grouped by the gas used (^{3}He or ^{129}Xe), then by the type of repeated outcome reported (repeated scans, and/or intra/interobserver repeated quantification), for a total of six groups. If studies reported multiple repeated outcome types (i.e., repeated scans and repeated analysis), the study appeared in multiple groups for each repetition type assessed. The following three factors were considered for the grade of the quality of evidence: inconsistency (heterogeneity of results and methods), imprecision (smaller sample sizes yield greater uncertainly and imprecision of results), and indirectness (repeatability assessed as primary aim). For the purposes of this study, COSMIN risk of bias was not evaluated because it focused on methodological reporting, rather than study design (i.e., acquisition or algorithmic methods, sample sizes, primary vs. secondary aim) and measurement repeatability results. Table S1 provides definitions for each factor and details regarding how downgrading was assessed. The GRADE certainty of combined evidence for each group begins as "high" and is downgraded to "moderate," "low," or "very low" if appropriate based on the three considered factors.

2.4 | Data Extraction

All study characteristics and summary statistics were extracted by one author (V.M.D.). The following data were extracted using a standardized form: first author, year of publication, title, sample size, population description, MRI scanner make and model, MRI field strength, radiofrequency coil type, type of gas (i.e., ^{3}He or ^{129}Xe), polarization method and equipment, gas dosing, VDP (or equivalent outcome measure) quantification method, bias field correction approach, number of observers, time between scans, reported outcome measure(s), and reported statistical test(s): absolute difference, percent coefficient of variation, Bland–Altman limits of agreement, coefficient of reproducibility, or the intra-class correlation coefficient. If studies reported multiple values for the collected data, all values were collected in this review. Extracted data are summarized in tabular form.

3 | Results

After identifying records and removing duplicates with the Covidence software, 379 records were identified (Figure 1). Abstracts were then screened for relevance, leaving 96 (26%) potentially relevant records with repeated HP MRI acquisition or quantification and 274 (74%) irrelevant records excluded. Full-text assessment of 96 potentially relevant records was performed, leaving 22 (23%) eligible and 74 (77%) excluded records. Specific reasons for full-text exclusions of studies are shown in Table S2. Table 1 provides a summary of the 22 included studies in alphabetical order with associated participant population, sample size, and MRI VDP (or similar measure) value. Table 2 provides a summary of the acquisition and quantification methodology, and Table 3 summarizes other elements of study design and statistical outcomes of the 22 included studies.

3.1 | Participants

The included studies explored nine different participant populations: CF [6, 41–49], COPD [5, 6, 50–52], asthma [6, 50, 53–56], lung cancer [5, 50], bronchiectasis [52], exercise-induced bronchoconstriction [57], horseshoe lung [50], primary ciliary dyskinesia [58], and healthy people [5, 41, 43, 48, 51, 53, 59, 60] (Table 4). Individual study sample sizes ranged from 6 to 40 participants, with 13 studies evaluating exclusively adult populations [5, 6, 42, 50–57, 59, 60], seven pediatric populations—defined as less than 18 years of age [41, 43, 45, 46, 48, 49, 58], and two in combination [44, 47].

3.2 | Design

The included studies employed a variety of study designs related to the number of sites for data collection, repeat type, and where

15222586, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/jmri.29746 by Test, Wiley Online Library on [03/03/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License



FIGURE 1 | PRISMA flow diagram of database search results.

applicable, repeat interval. Seventeen studies collected data at a single site [5, 6, 42–44, 46–48, 50–54, 57–60], three studies combined data from two sites [41, 55, 56], and two studies from four sites [45, 49]. Eight studies performed a single scan and compared multiple quantifications [6, 41, 42, 50, 55–57, 60], of which three compared quantifications by the same observer [6, 42, 56], and seven between multiple observers [6, 41, 50, 55–57, 60]. Thirteen studies performed same-day repeated scans [5, 43–46, 48, 49, 51, 53, 54, 56, 59, 60], and 13 performed repeated scans separated by more than 1 day [5, 42–44, 47–49, 51, 52, 55, 56, 58, 60]. For those separated by ≥1 day, the median time between them ranged from 1 day to 16 months.

3.3 | Image Acquisition

The included studies reported three different MRI vendors: General Electric [5, 6, 41, 42, 44, 45, 47, 49–51, 53–57, 59, 60], Siemens [43, 45, 49], and Philips [41, 45, 46, 49]. Three studies reported a combination of vendors [41, 45, 49], and three studies did not report vendors [48, 52, 58] (Table 5). There were nine studies that reported 1.5T field strength [5, 44, 46, 47, 50, 53, 54, 57, 59], eight using 3T [6, 42, 43, 45, 49, 51, 56, 60], two using a combination [41, 55] and three that did not report field strength [48, 52, 58]. For hyperpolarized gas imaging acquisition, 12 studies used 2D multi-slice sequences [6, 29, 41, 42, 45, 47, 49, 51, 54, 55, 57, 60] and seven used 3D sequences [5, 44, 46, 50, 53, 56, 59]; three did not report sequence details [48, 52, 58]. Seventeen used gradient echo sequences [6, 41–47, 49–51, 53–57, 60], and two used a non-gradient echo sequence [5, 59]. For specialized HP MRI hardware, twelve used commercially built radiofrequency coils [5, 6, 42–44, 49–51, 53, 54, 59, 60], two used home-built coils [46, 56], two used a combination [41, 55], and six did not report [45, 47, 48, 52, 57, 58]. Of these, eight studies used flexible coils [5, 43, 44, 49, 50, 53, 54, 59], six used rigid coils [6, 42, 46, 51, 56, 60], and two used a combination of coil types [41, 55].

3.4 | Gas

The included studies used different hyperpolarized gases and techniques for dosing and administration. Eleven of the studies utilized ^{3}He [6, 42, 46, 47, 51, 52, 54, 55, 57, 59, 60], nine used ^{129}Xe [41, 43–45, 48, 49, 53, 56, 58], and two used a combination of both gases [5, 50] (Table 6). Of the studies using ^{129}Xe, four used an enriched blend [41, 44, 53, 56], five did not specify [5, 45, 48–50, 58], and one used multiple gas blends [43]. Twelve studies used commercially built gas polarizers [6, 41–43, 46, 47, 51, 55–57, 59, 60], one used a home-built polarizer [44] and two used multiple types [5, 50]. Gas was produced at a range of different volumes and administered at different initial lung inflation volumes. Seven studies used a standard mixture of HP gas and buffer gas for all participants [5, 41, 50, 53, 54, 56, 59], nine studies tailored the ratio of HP gas to buffer gas and total bag volume to the participant [6, 42–44, 46, 49, 51, 55, 60], five used multiple approaches [41, 46, 49, 50, 56], and seven studies did not report gas ratios [5, 45, 47, 48, 52, 57, 58]. A total of 15 distinct methods were reported for gas dosing and administration across the 22 studies.

3.5 | Image Quantification

There were two main categories of image quantification methods: semiautomated segmentation [5, 6, 41–50, 53, 54, 56, 57, 59] and manual segmentation [6, 45, 49, 51, 55, 57, 60]; two

15222586, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/jmri.29746 by Test, Wiley Online Library on [03/03/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

TABLE 1 | Population characteristics and HP MRI outcome measures of included studies.

Study	Population	Sample size (*n*)	VDV/P	VV/%
1. Bashi et al. (2024)	PCD	7	3.68%[a]	NR
2. Couch et al. (2019)	HC	8	5.96%[a]	NR
	CF	18	15.96%[a]	
3. Diamond et al. (2023)	HC	4	NR	NR
	CF	12		
4. Ebner et al. (2017)	HC	10	5.6%[a]	NR
	Asthma	20	8.7%[a]	
5. Horn et al. (2014)	HC	13	NR	92.5%[a]
6. Hughes et al. (2018)	Horseshoe lung	1	NR	NR
	Asthma	1		
	COPD	4		
	Lung cancer	6		
7. Kirby et al. (2012)	CF, COPD and Asthma	15	0.92 L[a]	NR
8. Kirby et al. 2011)	CF	12	0.93 L[a]	NR
9. Marshall et al. (2021)	Asthma	33	NR	90.8%
10. Mathew et al. (2008)	HC	8	80 cm^3[a]	NR
	COPD	16	70 cm^3[a]	
11. Munidasa et al. (2023)	HC	7	2.65%[a]	NR
	CF	15	8.57%[a]	
12. Niles et al. (2013)	Asthma	13	252 mL[a]	5.37%[a]
13. Parraga et al. (2008)	HC	32	52 cm^3[a]	NR
14. Roach, et al. (2022)	CF	37	9.20%[a]	NR
15. Smith, et al. (2020)	CF	29	9.5%[a]	NR
16. Stewart, et al. (2018)	HC	19		98.4%[a]
	COPD	5		71.4%[a]
	NSCLC	16		79.6%[a]
17. Svenningsen et al. (2021)	Asthma	7	NR	11%[a]
18. Svenningsen et al. (2014)	COPD	9	21%	NR
	Non-CF Bronchiectasis		18%	
19. Walkup et al. (2024)	CF	38	5.0%[c]	NR
20. Woodhouse et al. (2009)	CF	5		NR
21. Zha et al. (2019)	CF	24	25.5%	NR
22. Zha et al. (2016)	EIB	6	1.11%[a]	NR

Abbreviations: CF = cystic fibrosis; COPD = chronic obstructive pulmonary disease; EIB = exercise-induced bronchoconstriction; HC = healthy control; NR = not reported; NSCLC = nonsmall-cell lung cancer; PCD = primary ciliary dyskinesia; VDV/P = average ventilation defect volume or percent (or equivalent metric); VV/% = average ventilated volume or percent (or equivalent metric).
[a]Multiple value are reported in the study; the first reported value is included here.

studies did not report their approach [52, 58] (Table 7). Five studies used bias field corrections to mitigate radiofrequency inhomogeneity [43, 45, 47, 49, 57], two explicitly reported not using any bias field correction [51, 54], and the rest did not report their bias field correction approach. Of the four studies that used bias field corrections, all four used an N4ITK correction, and one of these compared a linear RF correction to an N4ITK correction [45]. The semiautomated methods included various underlying algorithms to define ventilation versus ventilation defect within the lungs, including linear

15222586, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/jmri.29746 by Test, Wiley Online Library on [03/03/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

TABLE 2 | Study-specific acquisition and quantification methodology.

Study	Vendor	Field strength	Sequence	Gas	Algorithm	Bias field correction
1. Bashi et al. 2024)	NR	NR	NR	Xe	Not stated	NR
2. Couch et al. (2019)	General Electric Philips	1.5 T 3 T	2D GE	Xe	Linear binning	NR
3. Diamond et al. 2023)	NR	NR	NR	Xe	K-means clustering	NR
4. Ebner et al. (2017)	General Electric	1.5 T	3D GE	Xe	Linear Binning	NR
5. Horn et al. (2014)	General Electric	1.5 T	3D nGE	He	Threshold-based region growing	NR
6. Hughes et al. (2018)	General Electric	1.5 T	3D GE	Xe He	Thresholding & spatial fuzzy C-means clustering	NR
7. Kirby et al. (2012)	General Electric	3 T	2D GE	He	Manual & K-means clustering	NR
8. Kirby et al. (2011)	General Electric	3 T	2D GE	He	K-means clustering	NR
9. Marshall et al. (2021)	General Electric	1.5 T	2D GE	He	Threshold-based region growing	No
10. Mathew et al. (2008)	General Electric	3 T	2D GE	He	Manual	No
11. Munidasa et al. (2023)	Siemens	3 T	2D GE	Xe	Mean-anchored thresholding	N4ITK
12. Niles et al. (2013)	General Electric	1.5 T 3 T	2D GE	He	Manual Segmentation	NR
13. Parraga et al. 2008)	General Electric	3 T	2D GE	He	Manual	NR
14. Roach et al. (2022)	General Electric Siemens Philips	3 T	2D GE	Xe	Manual & mean-anchored thresholding	N4ITK & Linear RF
15. Smith et al. (2020)	General Electric	1.5 T	3D GE	Xe	Spatial fuzzy C-means clustering	NR
16. Stewart et al. (2018)	General Electric	1.5 T	3D nGE	Xe He	Threshold-based region growing	NR
17. Svenningsen et al. (2021)	General Electric	3 T	3D GE	Xe	K-means clustering	NR
18. Svenningsen et al. (2014)	NR	NR	NR	He	Not stated	NR
19. Walkup et al. (2024)	General Electric Siemens Philips	3T	2DGE	Xe	Manual & mean-anchored thresholding	N4ITK
20. Woodhouse et al. (2009)	Philips	1.5 T	3D GE	He	SNR-anchored thresholding	NR

(Continues)

15222586, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/jmri.29746 by Test, Wiley Online Library on [03/03/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

TABLE 2 | (Continued)

Study	Vendor	Field strength	Sequence	Gas	Algorithm	Bias field correction
21. Zha et al. (2019)	General Electric	1.5 T	2D GE	He	K-means clustering	N4ITK
22. Zha et al. (2016)	General Electric	1.5 T	2D GE	He	Manual & K-means clustering	N4ITK

Abbreviations: GE = gradient echo; He = helium-3; nGE = non-gradient echo; NR = not reported; Xe = xenon-129.

binning [41, 53], clustering including k-means and fuzzy c-means [6, 42, 44, 47, 48, 50, 56, 57], mean-anchored thresholding [43, 45, 61], threshold-based region growing [5, 54, 59] and other thresholding methods [46, 50]. From these various methods, six different terms for similar metrics that quantify defect were reported: ventilation volume (VV) [6, 46, 50, 54], ventilation volume percent (VV%) [5, 46, 54, 55, 59], ventilation defect volume whole-lung (VDV) [6, 42, 55] or single slice [51, 60], ventilation defect percent whole-lung (VDP) [41–45, 47–49, 52, 53, 56–58] or single slice [43], and reader defect volume [49].

3.6 | Reliability and Measurement Error

Variability of VDP and equivalent metrics was assessed using absolute difference [43, 54], coefficient of variation [5, 6, 42, 43, 54, 59, 60], Bland–Altman bias (mean difference) [41–50, 53–57], limits of agreement [41–50, 53–56], coefficient of reproducibility [43], and intraclass correlation [5, 6, 41, 43, 44, 47, 48, 50–56, 58, 59] (Table 7). Reported findings for the ICC and Bland–Altman analysis are presented in Figure 2. ICC ranged from 0.46 to 1.0, with six studies with ICC < 0.70. Bland–Altman bias range ranged from −6.9% to 20%, with the majority of studies near zero bias. We note that the one study that reported the 20% bias was using a basic thresholding method, against which an improved, semi-automated fuzzy c-means method was compared showing a bias of −0.9% (see two side-by-side studies labeled "6" in Figure 2B) [50]. Fifteen of the studies assessed the reliability of VDP and similar metrics [5, 6, 41, 43, 44, 47, 48, 50–56, 58] and 16 studies assessed measurement error of VDP and similar metrics [5, 6, 42–50, 54, 56, 57, 59, 60].

3.7 | Good Measurement Properties (GMP) and GRADE Summary

The GMP ratings are shown in Table 8, along with a summary of the study repeat type, repeat interval, and reported statistical metrics. For the GMP analysis, aims were rated based on whether they assessed reliability ($n = 8$), measurement error ($n = 9$), or both ($n = 19$). Of the 27 aims that assessed reliability, 19 were rated Sufficient (ICC ≥ 0.70), and eight were rated Insufficient (ICC < 0.70) based on the GMP guidelines. All 29 aims assessing Measurement Error were rated as indeterminate as there is no consensus on MIC for VDP to be used in the GMP analysis.

Study aims were categorized into six different groups for the GRADE analysis based on the distinct aim explored, with each group receiving a "Very Low" rating (Table 8). "Very Low" ratings were driven by different image acquisition and VDP quantification methods in five groups (i.e., very serious inconsistency), small sample sizes in four groups (i.e., serious or very serious imprecision), or because variability was not assessed as a primary aim (i.e., serious indirectness). Full details for inconsistency, imprecision, and indirectness are shown in Table 8, with definitions of all criteria in Table S1. The quantitative results in Figure 2 are presented by GRADE group using different colors.

4 | Discussion

VDP, derived from HP MRI, is a feasible and sensitive measure of lung function with applicability across a spectrum of pulmonary disorders [62]. Additionally, there has been recent FDA approval for the use of hyperpolarized 129-xenon gas as a contrast agent for use with pulmonary MRI in those 12 years of age and older; however, approval of a quantification methodology and of VDP as an outcome measure is yet to occur [63]. Further, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) and Good Manufacturing Process (GMP) have authorized the Xenon Polariser Laboratory at the University of Sheffield to use hyperpolarised 129-xenon gas for human use and use in clinical trials [64]. To continue to progress in clinical implementation, the variability of VDP must be well understood. Thus, in this systematic review, we summarized the current literature regarding the variability of VDP. Overall, there was high reliability and low test–retest, intraobserver, and interobserver variability of VDP reported within individual studies, as outlined in Figure 2. The main result of our study is that, despite studies from single centers demonstrating low variability of VDP, the inconsistent methodological approaches in image acquisition, post-processing techniques, and statistical analyses between studies precluded a meta-analysis of pooled variability data and a consequent very low GRADE certainty of combined evidence. Additionally, the lack of consensus regarding the MIC for VDP prevented the assessment of measurement error. This study highlights the importance of ongoing efforts to standardize VDP quantification to allow for multi-center interoperability as well as meaningful clinical interpretation of quantitative HP MRI.

The main methodological differences between the studies that preclude direct comparison can be grouped in three distinct categories: (1) disease under study, (2) image acquisition protocols, and (3) image quantification methodologies. First, the included studies evaluated seven different lung conditions, and not all studies included healthy participants for comparison. Given the unique manifestations of different lung diseases, whether there is disease-specific physiologic variability in VDP is not

15222586, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/jmri.29746 by Test, Wiley Online Library on [03/03/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

TABLE 3 | Study design, reported statistics, and quality assessment for included studies.

Study	Repeat type	Scan repeat interval	Bland–Altman bias (LoA)	ICC	R or ME	GMP	
						R	ME
1. Bashi et al. (2024)	Scans	28 days	NR	0.47	R	−	NA
2. Couch et al. (2019)	Interobserver	NA	0.14 (−2.7, 3.0)	0.99	R	+	NA
3. Diamond et al. (2023)	Scans	20 min	0.22 (−3.06, 3.49)	0.48	Both	−	?
4. Ebner et al. (2017)	Scans	1 month	−0.04 (−3.19, 3.10)	0.60	Both	−	?
5. Horn et al. (2014)	Scans	10 min	−0.88 (−2.4, 0.64)	0.98	R	+	?
6. Hughes et al. (2018)	Scans—1 breath	≤10 min	0.72 (−3.0, 4.44)[d]	0.96	Both	+	?
7. Kirby et al. (2012)	Scans—2 breaths	≤10 min	0.20 (−6.14, 6.55)[d]	0.88	Both	−	?
8. Kirby et al. (2011)	Interobserver	NA	−0.9 (−20.0, 18.2) [c]	0.58[c]	Both	+	?
9. Marshall et al. (2021)	Interobserver	NA	−1.1 (−6.7, 4.5) [c]	0.85[c]	Both	+	?
10. Mathew et al. (2008)	Intraobserver	NA	NR	0.98[c]	Both	+	?
11. Munidasa et al. (2023)	Interobserver	NA	NR	0.96[c]	Both	+	?
12. Niles et al. (2013)	Scans	7 days	−3 (−11, 5)	NR	ME	NA	?
13. Parraga et al. 2008)	Intraobserver	NA	NR	NR	ME	NA	?
14. Roach et al. (2022)	Scans	5 mins	0.12 (−1.86, 2.1)	1.00	Both	+	?
15. Smith et al. (2020)	Scans	7 mins	NR	0.96	R	+	NA
16. Stewart et al. (2018)	Scans	7 days	NR	0.98	R	−	NA
17. Svenningsen et al. (2021)	Scans	Same-day[a]	−0.1 (−4.12, 3.91)	0.93	Both	+	?
18. Svenningsen et al. (2014)	Scans	1 month	−1.25 (−8.80, 6.31)	0.68	Both	−	?
19. Walkup et al. (2024)	Scans	7 days	NR	0.89[c]	R	+	NA
20. Woodhouse et al. (2009)	Interobserver	NA	2.91 (−4.52, 10.30)	0.91[c]	R	+	NA
21. Zha et al. (2019)	Scans	7 mins	NR	NR	ME	NA	?
1. Bashi et al. (2024)	Scans	7 days	NR	NR	ME	NA	?
	Interobserver	NA	NR	NR	ME	NA	?
2. Couch et al. (2019)	Scans	8 h	0.5 (−3.85, 4.35)[c]	NR	ME	NA	?
3. Diamond et al. (2023)	Scans	15 mins	0.2 (−1.4, 1.8)	0.99	Both	+	?
4. Ebner et al. (2017)	Scans	16 months	0.8 (−6.9, 8.5)[c]	0.97	Both	+	?
5. Horn et al. (2014)	Scans	Multi[b]	NR	0.54	Both	−	?
6. Hughes et al. (2018)	Scans	Multi[b]	NR	0.46	Both	−	?
7. Kirby et al. (2012)	Scans	24 h	−3 (−14, 8)[c]	NR	Both	+	?
8. Kirby et al. (2011)	Interobserver	NA	0 (−4, 3)[c]	0.97[c]	Both	+	?
9. Marshall et al. (2021)	Intraobserver	NA	0 (−3, 2)[c]	0.99[c]	Both	+	?
10. Mathew et al. (2008)	Scans	3 weeks	NR	0.61[c]	R	+	NA
11. Munidasa et al. (2023)	Scans	36 mins	0.12 (−3.2, 3.4)	NR	ME	NA	?
12. Niles et al. (2013)	Scans	1 month	NR	NR	NA	NA	NA
13. Parraga et al. 2008)	Scans	30 mins	−3.7 (−7.7, 0.15)	NR	ME	NA	?
14. Roach et al. (2022)	Scans	1–2 weeks	2.25 (−6.04, 10.54)	0.95	Both	+	?
15. Smith et al. (2020)	Interobserver	NA	0.22 (LoA NR)	NR	ME	NA	?

Abbreviations: GMP = good measurement properties; GMP: sufficient (+); insufficient (−); indeterminate (?); not applicable (NA); ICC = intraclass correlation coefficient; LoA = limits of agreement; ME = measurement error; R = reliability.
[a]Time difference not specified.
[b]Twice on day 1, once on day 2, and once 2 weeks post day 1.
[c]Multiple values reported in the study, the first reported value is included here (except study 5 where the first reported value from the semi-automated approach is included here).
[d]Figure reported in the paper, values acquired by personal communication with authors.

15222586, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/jmri.29746 by Test, Wiley Online Library on [03/03/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

TABLE 4 | Study population and design.

Study design element	Number of studies
Total included studies	22
Population	
Disease group	
Healthy	8 (36%)
Asthma	6 (27%)
Bronchiectasis	1 (5%)
Chronic obstructive pulmonary disease	5 (23%)
Cystic fibrosis	10 (45%)
Exercise-induced bronchoconstriction	1 (5%)
Horseshoe lung	1 (5%)
Lung cancer	2 (9%)
Primary ciliary dyskinesia	1 (5%)
Adult	13 (59%)
Pediatric	7 (32%)
Adult and pediatric	2 (9%)
Number of sites	
1 Site	17 (77%)
2 Sites	3 (14%)
4 Sites	2 (9%)
Scans	
Observers	
Single observer	3 (14%)
Multiple observers	7 (32%)
Not reported	14 (64%)
Same-day repeat	13 (59%)
Repeat visit	13 (59%)
Short-term ≤1 month	12 (45%)
Long-term ≥1 month	1 (5%)
Single scan—Repeat quantification	8 (36%)

TABLE 5 | Image acquisition methods.

Image acquisition element	Number of studies
MRI Specs	
General Electric	17
Signa HDx	9
Excite	5
Discovery	2
Siemens	3
Magnetom prismafit	3
Philips	4
Eclipse	1
Achieva	2
Field strength	
1.5 Tesla	9
3 Tesla	8
1.5 and 3 Tesla	2
Not reported	3
Sequence	
Excitation scheme	
2D	12
3D	7
Not reported	3
Gradient echo	16
Non-gradient echo	2
No sequence reported	3
Coil specs	
Type	
Flexible	8
Rigid	6
Manufacturer	
Home built	2
Commercial	12
Multiple coils	2
Not reported	6

well understood. Disease-specific variability of spirometric outcomes has not been well established either; however, attempts have been made to define this in CF, COPD, and interstitial lung disease [65–68]. It has been shown that only a small amount (2%–4%) of spirometric variability can be explained by patient characteristics such as age, sex, height, smoking status, and FEV_1 [69]. Taking disease-specific variability into consideration may help to explain some of the remaining variability in spirometric outcomes and should be considered when reporting the variability of VDP. Disease-specific differences have been considered in single-center investigations of VDP in people with CF [42], COPD [6], and asthma [6, 27, 28], each reporting a disease-specific MIC. The majority of these studies have actually recommended that the clinically relevant threshold for VDP should be ~2% [27, 28, 45]; however, this value requires validation in larger and broader patient cohorts for further confidence in interpretation.

Second, there were methodological differences between the included studies with respect to MRI hardware, pulse sequences, and gas dosing and administration procedures.

15222586, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/jmri.29746 by Test, Wiley Online Library on [03/03/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

TABLE 6 | Hyperpolarized gas characteristics, equipment, and dosing.

Characteristics	Number of Studies
Gas	
Helium-3	11
Xenon-129	9
Unspecified	6
Enriched	4
Multiple blends	1
Combination of gasses	2
Polarizer	
Commercial	12
Home built	1
Multiple	2
Not reported	6
Total gas dosing volume	
1 L	13
1/6 TLC	2
0.4–1 L (height dependent)	1
Not reported	7
Initial lung volume	
Functional residual capacity	15
Multiple methods	1
Not reported	7
Dosing method	
Total different approaches	15
Participant dependent dosing	9
Standard dosing for all participants	7
Multiple methods	5
Not reported	7

TABLE 7 | Image quantification and statistical analysis methods.

Quantification and/or analysis specification	Number of studies
Pipeline	
Semiautomated	17
Manual	7
Not reported	2
Bias field correction	
Used	4
Not used	3
Not reported	15
Underlying algorithm	
Linear binning	2
K-means or fuzzy c-means clustering	8
Mean-anchored thresholding	3
Other thresholding	5
Outcome measure	
Ventilation volume (VV)	4
Ventilation volume percent, (VV%)	5
Ventilation defect volume (VDV)	3
Centre slice only	2
Ventilation defect percent (VDP)	13
Single slice only	1
Reader defect volume	1
Statistical test	
Absolute difference	2
Coefficient of variation	7
Bland Altman	15
Limits of agreement	14
Coefficient of reproducibility	1
Intra-class correlation coefficient	16

Recommendations for image acquisition protocols across the major MRI vendors have now been published [12]; however, only three of the 21 included studies were conducted after these recommendations were published, and head-to-head cross-platform comparisons have yet to be performed. Reassuringly, however, studies comparing VDP between 2D versus 3D pulse sequences [70, 71] and gradient echo versus balanced steady-state free precession sequences [72] have shown these technical factors to have minimal impact on VDP. Furthermore, studies included in this review included 15 different hyperpolarized gas dosing strategies, included both ^{3}He and ^{129}Xe, and inconsistently reported gas polarization or dose equivalent volume. Studies directly comparing the use of different inhaled gases show that they are not comparable, as ^{3}He VDP is consistently lower than that of ^{129}Xe [5–7]. Further, systematic differences in lung inflation can bias results, with lower lung inflation volumes shown to result in higher VDP [32]. Additionally, the methodology for obtaining the anatomical images taken with traditional proton MRI techniques may impact the calculated VDP. Though no studies have directly assessed the impacts of moving participants and switching from the specialized ^{129}Xe chest coil to a ^{1}H coil versus using the embedded body coil without moving the participants, a study explored the impacts of

15222586, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/jmri.29746 by Test, Wiley Online Library on [03/03/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

FIGURE 2 | Plot presenting reported outcomes for each aim from each included study numbered as in Table 1. ICC (A) and Bland–Altman Bias (points) and Limits of Agreement (dashed vertical lines) (B) from each study reporting VDP or VV%. In panel A, the red dashed line represents an acceptable ICC (0.70). In panel B, the navy dashed line represents no bias. High reliability and low variability of VDP were found in individual studies. Xe-S = Xe repeated scan; Xe-E = Xe interobserver repeat; Xe-A = Xe intraobserver repeat; He-S = He repeated scan; He-E = He interobserver repeat; He-A = He intraobserver repeat.

obtaining the anatomical image during the same breath-hold as the ^{129}Xe image and during a second volume-matched breath hold found significant differences in the resulting VDP [50]. Finally, the dose equivalent volume (DEV) of the inhaled HP gas (which is the product of the isotopic fraction, nuclear spin polarization, and the total volume of the inhaled HP gas) is related directly to the observed signal-to-noise ratio (SNR) in HP MRI ventilation imaging [12, 71] and is inconsistently reported in the included studies. The impact of SNR on variability has not been thoroughly assessed, but it has been suggested that a minimum SNR threshold must be met to ensure consistent VDP quantification [71, 73] and its impact on outcome variability has not been robustly assessed. Further efforts to standardize recommendations around lung inflation volume, DEV, and SNR, similar to work done on acquisition protocols [12], are necessary next steps towards inter-institutional standardization and better understanding of these factors on the variability of VDP.

Third, in the reviewed studies, there was a very wide variety of image analysis pipelines for the segmentation of images and the definition of defect, which could have a significant impact on the variability of VDP. The major differences in the pipelines include the use of manual or semi-automated approaches, the nature of the underlying quantification algorithm, and the definition of "defect." It is also important to note that these sources of variability are also present in the assessment of lung volume from anatomical scans used in conjunction with ventilation scans to assess "defect" in these methodologies. Over time, novel approaches have been developed and currently there is no clear "gold standard" for the definition of VDP. Current manual approaches require highly trained personnel and are subject to observer bias. Semi-automated methods have been shown to be less variable than manual methods [6, 50], though they are still subject to observer bias and bias introduced by varying underlying algorithms and definitions of ventilation defect. We also note

15222586, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/jmri.29746 by Test, Wiley Online Library on [03/03/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

TABLE 8 | GRADE for all groups of studies.

Group		Studies, no. of aims	Factor	Rating	Grade
^{129}Xe	Repeated scans	(Bashi, 2024), 1	Inconsistency	Very serious	Very low
		(Diamond, 2023), 2	Imprecision	Acceptable	
		(Ebner, 2017), 1	Indirectness	Acceptable	
		(Munidasa, 2023), 2			
		(Niles, 2013), 1			
		(Roach, 2022), 1			
		(Smith, 2020), 2			
		(Stewart, 2018), 1			
		(Svenningsen, 2021), 1			
		(Walkup, 2024), 2			
	Interobserver repeat	(Couch, 2019), 1	Inconsistency	Very serious	Very low
		(Hughes, 2017), 1	Imprecision	Serious	
		(Niles, 2013), 1	Indirectness	Acceptable	
		(Svenningsen, 2021), 1			
	Intraobserver repeat	(Svenningsen, 2021), 1	Inconsistency	Acceptable	Very low
			Imprecision	Very Serious	
			Indirectness	Acceptable	
^{3}He	Repeated scans	(Horn, 2014), 2	Inconsistency	Very serious	Very low
		(Kirby, 2011), 1	Imprecision	Acceptable	
		(Marshall, 2021), 1	Indirectness	Serious	
		(Matthew, 2008), 2			
		(Parraga, 2008), 2			
		(Stewart, 2018), 1			
		(Svenningsen, 2014), 1			
		(Woodhouse, 2009), 1			
		(Zha, 2019), 1			
	Interobserver repeat	(Hughes, 2017), 1	Inconsistency	Very serious	Very low
		(Kirby, 2012), 1	Imprecision	Very serious	
		(Parraga, 2008), 1	Indirectness	Acceptable	
		(Zha, 2016), 1			
	Intraobserver repeat	(Kirby, 2012), 1	Inconsistency	Very serious	Very low
		(Kirby, 2011), 1	Imprecision	Very serious	
			Indirectness	Acceptable	

that studies which conducted repeated scans versus repeated analyses (inter- or intra-observer) answer different fundamental questions about VDP repeatability, and so we grouped these separately for evaluation of combined evidence.

The impacts of using specific clustering and thresholding methods to define VDP have been explored elsewhere and underscore the inappropriateness of directly comparing or combining VDP derived using different pipelines. For instance, a comparison of VDP from linear binning and adaptive k-mean clustering highlights how each classifies signals differently and ultimately, classifies different defect volumes [73]. In a separate comparison of adaptive thresholding and k-means clustering, VDP was consistently higher with adaptive thresholding [74]. A threshold may be selected based on how well it discriminates between health and disease, and adjusting that threshold impacts what the

15222586, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/jmri.29746 by Test, Wiley Online Library on [03/03/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

algorithm defines as defect [20, 75]. Work exploring five different VDP quantification methods, including variations of linear binning and thresholding, found differences in the abilities for each method to distinguish health from disease that vary for different disease groups [76]. Additionally, some studies used bias field corrections to correct radiofrequency field inhomogeneities when using flexible vest coils [77]; however, the specific implications of using different bias-field correction tools on VDP are not well established, and there is no consensus on which bias-field correction is superior (or indeed, whether it is necessary at all). Future automated algorithms and/or deep learning models to quantify VDP have the potential to further eliminate variability from observers using manual or semi-automated approaches, thus improving the overall reliability of outcome measures, but no studies using these tools were included in this review. Further, there is a lack of literature exploring the impacts of the above-mentioned variables (i.e., algorithm used, bias field corrections, etc.) on the variability of the anatomical scans used to assess total lung volume. These variables in the assessment of total lung volume will directly impact the repeatability of VDP outcomes. Finally, some studies assessed the intra-observer variability of their quantification process, while others assessed inter-observer variability. However, not all studies reported whether VDP assessments were computed by one or many observers. Together, these differences across study designs limited the overall ability to pool data to provide systematic evidence and precluded the direct comparison of results between studies.

4.1 | Limitations

The primary limitation of this study is the potential for missed evidence. Literature may have been missed if it was not identified using our published search strategy (PROSPERO CRD42022328535) in one of the selected databases, reducing the number of possible studies included in the review. To mitigate this risk, the search strategy was bolstered by the manual addition of potentially eligible studies by all members of the authorship group, who are experts in the field. Gray literature was not included in this review, which may have included additional data not captured with our search strategy. Another limitation to note is that each of the 22 included studies was conducted at one of seven different sites, which could impact the generalizability of the results. Finally, the findings of this review are weakened by the inability to confidently group studies and perform a meta-analysis on the pooled results. We acknowledge that the COSMIN tool, though validated and standardized, may not capture all nuances associated with VDP measurement from HP MRI that is still an emerging field; thus, we used a modified version to focus only on GMP and GRADE, excluding the risk of bias tool. The COSMIN risk of bias checklist focuses on methodological reporting, making it less relevant to the objectives of this study. This modified tool allowed the results to focus primarily on study design and VDP measurement variability metrics.

4.2 | Conclusion

The reported variability of VDP is generally low in most individual studies, supporting its use as an imaging pulmonary outcome measure. However, direct comparison and aggregation of variability data across studies is not possible, primarily due to inconsistencies in study design and VDP quantification approaches. These study design inconsistencies, rather than fundamental flaws in the studies themselves, are what lead to the overall "very low" certainty of combined evidence reported in this systematic review. While the individual study results are reassuring, especially in the context of implementation of single-center longitudinal monitoring of disease progression and treatment response, this review has highlighted a clear need in the field to establish a standard VDP quantification methodology. This is especially relevant if this technique is to be used to aggregate or compare data between centers for clinical trial or registry purposes. Efforts towards standardizing quantification methods can be made through large-scale data registry projects that assess different methods and provide recommendations for standardization. This standardization effort is crucial to the advancement of HP MRI into clinical practice and clinical trials.

References

1. B. M. Liang, D. C. L. Lam, and Y. L. Feng, "Clinical Applications of Lung Function Tests: A Revisit," *Respirology* 17 (2012): 611–619.

2. W. McNulty and O. S. Usmani, "Techniques of Assessing Small Airways Dysfunction," *European Clinical Respiratory Journal* 1 (2014): 25898.

3. L. S. Mott, J. Park, C. P. Murray, et al., "Progression of Early Structural Lung Disease in Young Children With Cystic Fibrosis Assessed Using CT," *Thorax* 67 (2012): 509–516.

4. J. P. Mugler and T. A. Altes, "Hyperpolarized 129Xe MRI of the Human Lung," *Journal of Magnetic Resonance Imaging* 37 (2013): 313–331.

5. N. J. Stewart, H. F. Chan, P. J. C. Hughes, et al., "Comparison of 3He and 129Xe MRI for Evaluation of Lung Microstructure and Ventilation at 1.5T," *Journal of Magnetic Resonance Imaging* 48 (2018): 632–642.

6. M. Kirby, M. Heydarian, S. Svenningsen, et al., "Hyperpolarized 3He Magnetic Resonance Functional Imaging Semiautomated Segmentation," *Academic Radiology* 19 (2012): 141–152.

7. S. Svenningsen, M. Kirby, D. Starr, et al., "Hyperpolarized ^{3}He and ^{129}Xe MRI: Differences in Asthma Before Bronchodilation," *Journal of Magnetic Resonance Imaging* 38 (2013): 1521–1530.

8. Y. Shukla, A. Wheatley, M. Kirby, et al., "Hyperpolarized ^{129}Xe Magnetic Resonance Imaging. Tolerability in Healthy Volunteers and Subjects With Pulmonary Disease," *Academic Radiology* 19 (2012): 941–951.

9. B. Driehuys, S. Martinez-Jimenez, Z. I. Cleveland, et al., "Chronic Obstructive Pulmonary Disease: Safety and Tolerability of Hyperpolarized ^{129}Xe MR Imaging in Healthy Volunteers and Patients," *Radiology* 262 (2012): 279–289.

10. L. L. Walkup, R. P. Thomen, T. G. Akinyi, et al., "Feasibility, Tolerability and Safety of Pediatric Hyperpolarized ^{129}Xe Magnetic Resonance Imaging in Healthy Volunteers and Children With Cystic Fibrosis," *Pediatric Radiology* 46 (2016): 1651–1662.

11. N. Tsuchiya, M. L. Schiebler, M. D. Evans, et al., "Safety of Repeated Hyperpolarized Helium 3 Magnetic Resonance Imaging in Pediatric Asthma Patients," *Pediatric Radiology* 50 (2020): 646–655.

12. P. J. Niedbalski, C. S. Hall, M. Castro, et al., "Protocols for Multi-Site Trials Using Hyperpolarized ^{129}Xe MRI for Imaging of Ventilation, Alveolar-Airspace Size, and Gas Exchange: A Position Paper From the ^{129}Xe MRI Clinical Trials Consortium," *Magnetic Resonance in Medicine* 86 (2021): 2966–2986.

15222586, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/jmri.29746 by Test, Wiley Online Library on [03/03/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

13. Prescribing Information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214375s000lbl.pdf.

14. J. D. Peiffer, T. Altes, I. C. Ruset, et al., "Hyperpolarized 129Xe MRI, 99mTc Scintigraphy, and SPECT in Lung Ventilation Imaging: A Quantitative Comparison," *Academic Radiology* 31 (2024): 1666–1675.

15. E. E. de Lange, T. A. Altes, J. T. Patrie, et al., "Evaluation of Asthma With Hyperpolarized Helium-3 MRI: Correlation With Clinical Severity and Spirometry," *Chest* 130 (2006): 1055–1062.

16. L. J. Smith, G. J. Collier, H. Marshall, et al., "Patterns of Regional Lung Physiology in Cystic Fibrosis Using Ventilation Magnetic Resonance Imaging and Multiple-Breath Washout," *European Respiratory Journal* 52 (2018): 1800821.

17. M. Kirby, L. Mathew, A. Wheatley, G. Santyr, D. McCormack, and G. Parraga, "Chronic Obstructive Pulmonary Disease: Longitudinal Hyperpolarized (3)He MR Imaging," *Radiology* 256 (2010): 280–289.

18. M. Kirby, D. Pike, H. O. Coxson, D. G. McCormack, and G. Parraga, "Hyperpolarized 3He Ventilation Defects Used to Predict Pulmonary Exacerbations in Mild to Moderate Chronic Obstructive Pulmonary Disease," *Radiology* 273 (2014): 887–896.

19. N. Kanhere, M. J. Couch, K. Kowalik, et al., "Correlation of Lung Clearance Index With Hyperpolarized ^{129}Xe Magnetic Resonance Imaging in Pediatric Subjects With Cystic Fibrosis," *American Journal of Respiratory and Critical Care Medicine* 196 (2017): 1073–1075.

20. R. P. Thomen, L. L. Walkup, D. J. Roach, Z. I. Cleveland, J. P. Clancy, and J. C. Woods, "Hyperpolarized ^{129}Xe for Investigation of Mild Cystic Fibrosis Lung Disease in Pediatric Patients," *Journal of Cystic Fibrosis* 16 (2017): 275–282.

21. L. L. Walkup, K. Myers, J. El-Bietar, et al., "Xenon-129 MRI Detects Ventilation Deficits in Paediatric Stem Cell Transplant Patients Unable to Perform Spirometry," *European Respiratory Journal* 53 (2019): 1801779.

22. H. Marshall, A. Horsley, C. J. Taylor, et al., "Detection of Early Subclinical Lung Disease in Children With Cystic Fibrosis by Lung Ventilation Imaging With Hyperpolarised Gas MRI," *Thorax* 72 (2017): 760–762.

23. D. G. Mummy, S. J. Kruger, W. Zha, et al., "Ventilation Defect Percent in Helium-3 Magnetic Resonance Imaging as a Biomarker of Severe Outcomes in Asthma," *Journal of Allergy and Clinical Immunology* 141 (2018): 1140–1141.

24. D. G. Mummy, K. J. Carey, M. D. Evans, et al., "Ventilation Defects on Hyperpolarized Helium-3 MRI in Asthma Are Predictive of 2-Year Exacerbation Frequency," *Journal of Allergy and Clinical Immunology* 146 (2020): 831–839.

25. M. Kirby, L. Mathew, M. Heydarian, R. Etemad-Rezai, D. G. McCormack, and G. Parraga, "Chronic Obstructive Pulmonary Disease: Quantification of Bronchodilator Effects by Using Hyperpolarized He MR Imaging," *Radiology* 261 (2011): 283–292.

26. J. H. Rayment, M. J. Couch, N. McDonald, et al., "Hyperpolarised ^{129}Xe Magnetic Resonance Imaging to Monitor Treatment Response in Children With Cystic Fibrosis," *European Respiratory Journal* 53 (2019): 1802188.

27. R. L. Eddy, S. Svenningsen, D. G. McCormack, and G. Parraga, "What Is the Minimal Clinically Important Difference for Helium-3 Magnetic Resonance Imaging Ventilation Defects?," *European Respiratory Journal* 51, no. 6 (2018): 1800324, https://doi.org/10.1183/13993003.00324-2018.

28. M. J. McIntosh, A. Biancaniello, H. K. Kooner, et al., "129Xe MRI Ventilation Defects in Asthma: What Is the Upper Limit of Normal and Minimal Clinically Important Difference?," *Academic Radiology* 30, no. 12 (2023): 3114–3123, https://doi.org/10.1016/j.acra.2023.03.010.

29. S. Munidasa, R. Seethamraju, J. Au, et al., "Inter-Visit Reproducibility of Free-Breathing Lung Magnetic Resonance Imaging in Cystic Fibrosis," *Journal of Cystic Fibrosis* 20, no. Suppl 2 (2021): S80.

30. F. S. Alam, B. Zanette, S. Munidasa, et al., "Intra- and Inter-Visit Repeatability of 129Xenon Multiple-Breath Washout MRI in Children With Stable Cystic Fibrosis Lung Disease," *Journal of Magnetic Resonance Imaging* 58 (2023): 936–948.

31. A. M. P. M. Bovens, M. A. van Baak, J. G. P. M. Vrencken, J. A. G. Wijnen, and F. T. J. Verstappen, "Variability and Reliability of Joint Measurements," *American Journal of Sports Medicine* 18 (1990): 58–63.

32. P. J. Hughes, L. Smith, H.-F. Chan, et al., "Assessment of the Influence of Lung Inflation State on the Quantitative Parameters Derived From Hyperpolarized Gas Lung Ventilation MRI in Healthy Volunteers," *Journal of Applied Physiology* 126 (2019): 183–192.

33. P. W. Jones, K. M. Beeh, K. R. Chapman, M. Decramer, D. A. Mahler, and J. A. Wedzicha, "Minimal Clinically Important Differences in Pharmacological Trials," *American Journal of Respiratory and Critical Care Medicine* 189 (2014): 250–255.

34. M. J. Page, J. E. McKenzie, P. M. Bossuyt, et al., "The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews," *International Journal of Surgery* 372 (2021): n71.

35. J. Higgins, J. Thomas, J. Chandler, et al., *Cochrane Handbook for Systematic Reviews of Interventions*, 2nd ed. (Wiley, 2019).

36. Veritas Health Innovation, "Covidence Systematic Review Software," 2023.

37. L. B. Mokkink, M. Boers, C. P. M. van der Vleuten, et al., "COSMIN Risk of Bias Tool to Assess the Quality of Studies on Reliability or Measurement Error of Outcome Measurement Instruments: A Delphi Study," *BMC Medical Research Methodology* 20 (2020): 293.

38. C. A. C. Prinsen, L. B. Mokkink, L. M. Bouter, et al., "COSMIN Guideline for Systematic Reviews of Patient-Reported Outcome Measures," *Quality of Life Research* 27 (2018): 1147–1157.

39. L. B. Mokkink, H. C. W. de Vet, C. A. C. Prinsen, et al., "COSMIN Risk of Bias Checklist for Systematic Reviews of Patient-Reported Outcome Measures," *Quality of Life Research* 27 (2018): 1171–1179.

40. C. B. Terwee, C. A. C. Prinsen, A. Chiarotto, et al., "COSMIN Methodology for Evaluating the Content Validity of Patient-Reported Outcome Measures: A Delphi Study," *Quality of Life Research* 27 (2018): 1159–1170.

41. M. J. Couch, R. Thomen, N. Kanhere, et al., "A Two-Center Analysis of Hyperpolarized 129Xe Lung MRI in Stable Pediatric Cystic Fibrosis: Potential as a Biomarker for Multi-Site Trials," *Journal of Cystic Fibrosis* 18 (2019): 728–733.

42. M. Kirby, S. Svenningsen, H. Ahmed, et al., "Quantitative Evaluation of Hyperpolarized Helium-3 Magnetic Resonance Imaging of Lung Function Variability in Cystic Fibrosis," *Academic Radiology* 18 (2011): 1006–1013.

43. S. Munidasa, B. Zanette, M. Couch, et al., "Inter- and Intravisit Repeatability of Free-Breathing MRI in Pediatric Cystic Fibrosis Lung Disease," *Magnetic Resonance in Medicine* 89, no. 5 (2022): 2048–2061, https://doi.org/10.1002/mrm.29566.

44. L. J. Smith, A. Horsley, J. Bray, et al., "The Assessment of Short- and Long-Term Changes in Lung Function in Cystic Fibrosis Using ^{129}Xe MRI," *European Respiratory Journal* 56, no. 6 (2020): 2000441, https://doi.org/10.1183/13993003.00441-2020.

45. D. Roach, J. W. Plummer, J. Mata, et al., "Repeatability of Hyperpolarized ^{129}Xe MRI in Stable Pediatric CF Lung Disease via Quantitative Ventilation Defect Image Analysis From HyPOINT Study," *American Journal of Respiratory and Critical Care Medicine* 205 (2022): A2555.

46. N. Woodhouse, J. M. Wild, E. J. R. Van Beek, N. Hoggard, N. Barker, and C. J. Taylor, "Assessment of Hyperpolarized ^{3}He Lung MRI for Regional Evaluation of Interventional Therapy: A Pilot Study in Pediatric Cystic Fibrosis," *Journal of Magnetic Resonance Imaging* 30 (2009): 981–988.

15222586, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/jmri.29746 by Test, Wiley Online Library on [03/03/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

47. W. Zha, S. K. Nagle, R. V. Cadman, M. L. Schiebler, and S. B. Fain, "Three-Dimensional Isotropic Functional Imaging of Cystic Fibrosis Using Oxygen-Enhanced MRI: Comparison With Hyperpolarized ^{3}He MRI," *Radiology* 290 (2019): 229–237.

48. V. M. Diamond, R. L. Eddy, J. Bone, R. Gomilar, and J. H. Rayment, "Variability of Physiologic Testing and Magnetic Resonance Imaging Outcomes in Paediatric Populations," *American Journal of Respiratory and Critical Care Medicine* 67 (2023): 141–152.

49. L. L. Walkup, D. J. Roach, J. W. Plummer, et al., "Same-Day Repeatability and 28-Day Reproducibility of Xenon MRI Ventilation in Children With Cystic Fibrosis in a Multi-Site Trial," *Journal of Magnetic Resonance Imaging* (2024), https://doi.org/10.1002/jmri.29605.

50. P. J. C. Hughes, F. C. Horn, G. J. Collier, A. Biancardi, H. Marshall, and J. M. Wild, "Spatial Fuzzy c-Means Thresholding for Semiautomated Calculation of Percentage Lung Ventilated Volume From Hyperpolarized Gas and ^{1}H MRI," *Journal of Magnetic Resonance Imaging* 47 (2018): 640–646.

51. L. Mathew, A. Evans, A. Ouriadov, et al., "Hyperpolarized 3He Magnetic Resonance Imaging of Chronic Obstructive Pulmonary Disease. Reproducibility at 3.0 Tesla," *Academic Radiology* 15 (2008): 1298–1311.

52. S. Svenningsen, G. Paulin, D. G. McCormack, and G. Parraga, "Ventilation Abnormalities in Chronic Bronchitis and Bronchiectasis: Is There A Difference?," *American Journal of Respiratory and Critical Care Medicine* (2014). https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2014.189.1_MeetingAbstracts.A3570.

53. L. Ebner, M. He, R. S. Virgincar, et al., "Hyperpolarized 129Xenon Magnetic Resonance Imaging to Quantify Regional Ventilation Differences in Mild to Moderate Asthma: A Prospective Comparison Between Semiautomated Ventilation Defect Percentage Calculation and Pulmonary Function Tests," *Investigative Radiology* 52 (2017): 120–127.

54. H. Marshall, J. C. Kenworthy, F. C. Horn, et al., "Peripheral and Proximal Lung Ventilation in Asthma: Short-Term Variation and Response to Bronchodilator Inhalation," *Journal of Allergy and Clinical Immunology* 147 (2021): 2154–2161.

55. D. J. Niles, S. J. Kruger, B. J. Dardzinski, et al., "Exercise-Induced Bronchoconstriction: Reproducibility of Hyperpolarized ^{3}He MR Imaging," *Radiology* 266 (2013): 618–625.

56. S. Svenningsen, M. McIntosh, A. Ouriadov, et al., "Reproducibility of Hyperpolarized ^{129}Xe MRI Ventilation Defect Percent in Severe Asthma to Evaluate Clinical Trial Feasibility," *Academic Radiology* 28 (2021): 817–826.

57. W. Zha, D. J. Niles, S. J. Kruger, et al., "Semiautomated Ventilation Defect Quantification in Exercise-Induced Bronchoconstriction Using Hyperpolarized Helium-3 Magnetic Resonance Imaging: A Repeatability Study," *Academic Radiology* 23 (2016): 1104–1114.

58. L. Bashi, J. H. Rayment, R. L. Eddy, and S. D. Dell, "XE-Ing the Difference: Variability of Xenon MRI in Children With Primary Ciliary Dyskinesia," *American Journal of Respiratory and Critical Care Medicine* 209 (2024): A5163.

59. F. C. Horn, B. A. Tahir, N. J. Stewart, et al., "Lung Ventilation Volumetry With Same-Breath Acquisition of Hyperpolarized Gas and Proton MRI," *NMR in Biomedicine* 27 (2014): 1461–1467.

60. G. Parraga, L. Mathew, R. Etemad-Rezai, D. G. McCormack, and G. E. Santyr, "Hyperpolarized 3He Magnetic Resonance Imaging of Ventilation Defects in Healthy Elderly Volunteers. Initial Findings at 3.0 Tesla," *Academic Radiology* 15 (2008): 776–785.

61. L. Walkup, D. Roach, G. Santyr, et al., "^{129}Xe MRI Is a Repeatable Measure of Regional Ventilation in Children With Stable CF," *Journal of Cystic Fibrosis* 20 (2021): S253–S254.

62. C. S. Hall, "Invisible Insights: Probing Lung Function With ^{129}Xe MRI," *Academic Radiology* 31 (2024): 4217–4220.

63. Food and Drug Administration, "Xenoview," 2022.

64. MHRA, "Certificate of GMP Compliance of a Manufacturer(1),(2) Part 2 Human Investigational Medicinal Products."

65. L. B. Herpel, R. E. Kanner, S. M. Lee, et al., "Variability of Spirometry in Chronic Obstructive Pulmonary Disease," *American Journal of Respiratory and Critical Care Medicine* 173 (2006): 1106–1113.

66. P. J. Cooper, C. F. Robertson, I. L. Hudson, and P. D. Phelan, "Variability of Pulmonary Function Tests in Cystic Fibrosis," *Pediatric Pulmonology* 8 (1990): 16–22.

67. T. Veit, M. Barnikel, A. Crispin, et al., "Variability of Forced Vital Capacity in Progressive Interstitial Lung Disease: A Prospective Observational Study," *Respiratory Research* 21 (2020): 270.

68. B. G. Nickerson, R. J. Lemen, C. B. Gerdes, M. J. Wegmann, and G. Robertson, "Within-Subject Variability and per Cent Change for Significance of Spirometry in Normal Subjects and in Patients With Cystic Fibrosis," *American Review of Respiratory Disease* 122 (1980): 859–866.

69. P. L. Enright, K. C. Beck, and D. L. Sherrill, "Repeatability of Spirometry in 18,000 Adult Patients," *American Journal of Respiratory and Critical Care Medicine* 169 (2004): 235–238.

70. J. M. Wild, N. Woodhouse, M. N. J. Paley, et al., "Comparison Between 2D and 3D Gradient-Echo Sequences for MRI of Human Lung Ventilation With Hyperpolarized ^{3}He," *Magnetic Resonance in Medicine* 52 (2004): 673–678.

71. M. He, S. H. Robertson, S. S. Kaushik, et al., "Dose and Pulse Sequence Considerations for Hyperpolarized ^{129}Xe Ventilation MRI," *Magnetic Resonance Imaging* 33 (2015): 877–885.

72. U. A. Shammi, M. F. D'Alessandro, T. Altes, et al., "Comparison of Hyperpolarized ^{3}He and ^{129}Xe MR Imaging in Cystic Fibrosis Patients," *Academic Radiology* 29 (2022): S82–S90.

73. M. He, W. Zha, F. Tan, L. Rankine, S. Fain, and B. Driehuys, "A Comparison of Two Hyperpolarized ^{129}Xe MRI Ventilation Quantification Pipelines: The Effect of Signal to Noise Ratio," *Academic Radiology* 26 (2019): 949–959.

74. N. Radadia, Y. Friedlander, E. Priel, et al., "Comparison of Ventilation Defects Quantified by Technegas SPECT and Hyperpolarized ^{129}Xe MRI," *Frontiers in Physiology* 14 (2023): 14.

75. R. P. Thomen, A. Sheshadri, J. D. Quirk, et al., "Regional Ventilation Changes in Severe Asthma After Bronchial Thermoplasty With ^{3}He MR Imaging and CT," *Radiology* 274 (2015): 250–259.

76. D. J. Roach, M. M. Willmering, J. W. Plummer, et al., "Hyperpolarized ^{129}Xenon MRI Ventilation Defect Quantification via Thresholding and Linear Binning in Multiple Pulmonary Diseases," *Academic Radiology* 29 (2022): S145–S155.

77. J. Juntu, J. Sijbers, D. Van Dyck, and J. Gielen, "Bias Field Correction for MRI Images," in *Computer Recognition Systems*, ed. M. Kurzyński, E. Puchała, M. Woźniak, and A. żołnierek (Springer, 2005).

Supporting Information

Additional supporting information can be found online in the Supporting Information section.

15222586, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/jmri.29746 by Test, Wiley Online Library on [03/03/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License